Pinpoint Therapeutics, Inc., a Philadelphia, PA-based biopharmaceutical company focused on the development of novel autophagy inhibitors to treat cancer, raised $1 million in debt financing.
The round was led by Kairos Ventures.
Founded by researchers Ravi K. Amaravadi, M.D., and Jeffrey D. Winkler, Ph.D., from the University of Pennsylvania’s Abramson Cancer Center and the Department of Chemistry, and led by Christian Peters, M.D., Ph.D., Chief Executive Officer, Pinpoint develops new autophagy inhibitors for cancer treatments. Autophagy is a mechanism of cancer cell survival and drug resistance.
The company’s novel compounds target a recently discovered enzyme in the autophagy pathway called PPT1, which is highly expressed across most cancers. These inhibitors could be applied to a broad range of cancers alone or in combination with other treatments to overcome therapy resistance. Pinpoint will develop first-in-class autophagy inhibitors into clinical drugs for testing in a range of treatment-refractory cancers.
Pinpoint was launched in 2018 through PCI Ventures, a division of the Penn Center for Innovation (PCI) at the University of Pennsylvania.